No probiotic alone reliably kills H. pylori, but several strains significantly boost the effectiveness of standard antibiotic treatment. When probiotics are added to conventional therapy, eradication rates rise from roughly 62% to 79%, a meaningful jump that can make the difference between clearing the infection and needing a second round of treatment. The strains with the strongest evidence fall into three groups: Lactobacillus species, Saccharomyces boulardii (a beneficial yeast), and certain Bifidobacterium strains.
How Probiotics Work Against H. Pylori
H. pylori survives in the stomach by producing an enzyme called urease, which neutralizes stomach acid and creates a protective bubble around the bacterium. Probiotics attack this survival strategy from multiple angles. They produce lactic acid and other organic acids that directly inhibit H. pylori growth. They compete for the same binding sites on the stomach lining, physically blocking H. pylori from attaching. And they produce natural antimicrobial compounds called bacteriocins that damage the bacterium’s cell structure.
Perhaps most importantly, the organic acids produced by probiotic bacteria suppress that urease enzyme. Without it, H. pylori loses its ability to shield itself from stomach acid. Lab studies confirm that cell-free solutions from Lactobacillus species (essentially the acids and compounds they secrete, without the bacteria themselves) significantly reduce both H. pylori growth and urease activity across multiple antibiotic-resistant strains.
Lactobacillus: The Most Studied Group
Lactobacillus species have the deepest evidence base for H. pylori suppression. Two strains stand out in laboratory research: L. rhamnosus and L. acidophilus. In cell studies, L. rhamnosus blocked 96.7% of H. pylori from adhering to stomach lining cells, while L. acidophilus blocked 93.2%. Both strains also prevented H. pylori from invading deeper into cells by over 99%. These numbers come from controlled lab conditions, so the effect in a living stomach is less dramatic, but the mechanisms are real and consistent across studies.
L. reuteri has been tested more directly in human trials. In one pilot study, L. reuteri combined with a stomach acid reducer cleared H. pylori in 60% of participants, compared to 0% in the placebo group. Dosing matters: taking L. reuteri once daily at 100 million CFU without any acid-reducing medication was far less effective than twice-daily dosing with one. Later trials used higher doses, up to 1.4 billion CFU spread across the day, combined with acid-reducing medication for 28 days.
Saccharomyces Boulardii: Strong Side-Effect Relief
S. boulardii is a probiotic yeast, not a bacterium, which gives it a practical advantage: antibiotics don’t kill it. A meta-analysis of 19 studies covering over 5,000 patients found that adding S. boulardii to standard H. pylori treatment improved the eradication rate by 11%. But where this yeast really shines is in reducing the miserable side effects of triple or quadruple antibiotic therapy. Compared to antibiotics alone, S. boulardii cut diarrhea risk by 64%, reduced bloating by 51%, lowered constipation by 62%, and halved the incidence of nausea. It did not help with abdominal pain, vomiting, or taste disturbances.
This side-effect reduction has a practical consequence beyond comfort. One of the main reasons H. pylori treatment fails is that people stop taking their antibiotics early because the side effects are so unpleasant. By making the treatment more tolerable, S. boulardii may improve eradication rates partly by helping people finish the full course.
Bifidobacterium: Supporting Evidence
Bifidobacterium strains have less standalone evidence than Lactobacillus or S. boulardii, but one strain has solid human trial data. B. lactis Bb12 showed direct inhibitory effects on H. pylori in lab testing. In a six-week clinical study, 59 adults with H. pylori infections consumed yogurt containing Bb12 and L. acidophilus La5 twice daily. By the end of the trial, urease activity (a marker of active H. pylori infection) dropped significantly. The researchers noted that regular intake effectively suppressed H. pylori colonization, though the study used yogurt as the delivery method rather than capsules.
Single-Strain vs. Multi-Strain Formulas
You might assume that combining multiple probiotic strains into one supplement would work better than a single strain. The evidence doesn’t support that assumption for H. pylori specifically. A meta-analysis of 65 randomized controlled trials found that single-strain probiotics were generally equivalent to multi-strain mixtures, and for targeted conditions like H. pylori treatment, single-strain formulations were particularly effective. Multi-strain products can sometimes involve antagonistic interactions between strains that reduce overall efficacy. If you’re choosing a probiotic specifically for H. pylori support, picking a well-studied single strain is a reasonable strategy.
Timing and Duration
When you start probiotics relative to antibiotic treatment appears to matter. A meta-analysis of studies examining probiotic pretreatment found that starting probiotics before antibiotics raised eradication rates to about 80%, compared to 70% in control groups. This 10-percentage-point difference suggests that giving beneficial bacteria time to establish themselves in the gut before antibiotics arrive creates a more hostile environment for H. pylori from the outset.
Most successful clinical protocols run probiotics for two to four weeks before starting antibiotics, continue them throughout the antibiotic course (typically 14 days), and sometimes extend them for a few weeks after. The longest studied duration was 96 days of L. reuteri supplementation in one trial. Current H. pylori treatment guidelines recommend 14 days of antibiotic therapy as the standard duration, and probiotic supplementation generally follows that same window at minimum.
Dosing in Clinical Trials
The doses used in successful studies vary by strain, but most fall in the range of 100 million to 1 billion CFU per day. L. reuteri trials have used anywhere from 100 million CFU twice daily to 200 million CFU seven times daily (totaling 1.4 billion per day). The yogurt study with Bb12 used 10 million CFU per milliliter, consumed twice daily. Higher doses given more frequently tend to produce better results, though no study has pinpointed an exact optimal dose.
One consistent finding: probiotics without any conventional treatment barely move the needle. L. reuteri given once daily without acid-reducing medication cured only about 6% of infections. The real value of probiotics for H. pylori is as an add-on to standard antibiotic therapy, not a replacement for it. They improve your odds of clearing the infection on the first attempt and make the treatment process considerably less unpleasant.